Shionogi Company Limited

Shionigi & Co., Ltd.

Masami Eigyo

Akira Matsushita

Hiromu Matsumura

Toshisada Yano

Hiroshi Hashizume

Susumu Takada

Takashi Sasatani

Toshio Fujishita

Makoto Adachi

Hiroshi Matsumoto

Masaru Ogata

Kazuyuki Sasakura

Tsutomu Sugasawa

Katsumi Hirose

Nobuo Chomei

Ikuo Adachi

Motohiko Ueda

Takefumi Gemba

Hirohisa Shindo

Kazuo Kawasaki

An oxopyridinylquinoxaline derivative represented by the following Formula I or pharmaceutically acceptable salts thereof: ##STR1## wherein R.sup.1 is hydrogen, halogen, nitro, or trihalomethyl; R.sup.2 is hydrogen, halogen, nitro, cyano, trihalomethyl, carbamoyl, carbamoyl substituted with lower alkyl, sulfamoyl, or sulfamoyl substituted with lower alkyl; R.sup.3 is hydrogen, nitro, or halogen; R.sup.4 is hydrogen, lower alkyl, substituted lower alkyl, lower cycloalkyl, or substituted lower cycloalkyl; R.sup.5 's are substituents independently selected from the group consisting of halogen, nitro, cyano, lower alkyl, carbamoyl, and carbamoyl substituted with lower alkyl; and n is an integer of 0 to 4. The derivative works as an antagonistic agent against both the NMDA receptors and the AMPA receptors, so that it is effective as a therapeutic agent for neurological disorders caused by excitatory amino acids binding to the receptors.

Oxopyridinylquinoxaline derivative

The compounds of the present invention relates to tetrahydropyridine derivatives and have high affinity and specificity to .sigma. receptors, whereby these are thought to be effective for some psychoses.

Tetrahydropyridine derivatives

A compound of the formula: ##STR1## wherein n is an integer of from 2 to 6; and p and q each is an integer of 0 or 1, excluding the case where p is 0 when q is 1; or a pharmaceutically acceptable acid addition salt thereof. This compound has a high affinity and specificity to .sigma. receptors, and is thought to be effective for treatment of some psychoses.

A method useful for the treatment or prevention of diseases caused by a massive release of cerebral glutamate, in particular epilepsy and dementia, and pharmaceutical formulations therefor, which comprise, as an active ingredient, a therapeutically effective amount of methyl (+)-(4S)-4,7-dihydro-3-isobutyl-6-methyl-4-(3-nitrophenyl)thieno[2,3-b]pyr idine-5-carboxylate (S-312-d).

Formulation useful for the inhibition of massive release of cerebral

The present invention relates to tetrahydropyridine derivatives which have high affinity and specificity to .sigma. receptors, whereby these compounds are thought to be effective for treatment of some psychoses.

A compound of the formula: ##STR1## wherein R.sup.1 is hydrogen, or C.sub.1 14 C.sub.6 alkyl; n is an integer of from 2 to 3; Z.sup.1 is phenyl, benzyl, or isoxazolyl and each is optionally substituted by a halogen, a methoxy, or a methyl group; Z.sup.2 is hydrogen, C.sub.1 -C.sub.5 alkyl, allyl, unsubstituted phenyl, or phenyl substituted by halogen, methyl, or methoxy; or

Carbamoylpyrrolidone derivatives and drugs for senile dementia

Teirahydropyridine derivatives

A compound of the formula: ##STR1## (wherein R is phenoxy optionally substituted by a halogen, methoxy, or methyl group, ##STR2## one of A and B is ##STR3## and the other is &gt;CH.sub.2 ;

A compound of the formula: ##STR1## (wherein R is phenoxy optionally substituted by a halogen, methoxy, or methyl group, ##STR2## one of A and B is ##STR3## and the other is &gt;CH.sub.2 : R.sup.1 is hydrogen or C.sub.1 -C.sub.5 alkyl; Z.sup.1 is phenyl, benzyl, or isoxazolyl each optionally substituted by a halogen, methoxy, or methyl group; Z.sup.2 is hydrogen, C.sub.1 -C.sub.5 alkyl, C.sub.2 -C.sub.5 alkenyl, or phenyl optionally mono-, di-, or tri-substituted by a halogen, methoxy, or methyl group; or Z.sup.1 and Z.sup.2 taken together with the adjacent nitrogen atom may form 5-membered heterocyclic group; Z.sup.3 is C.sub.1 -C.sub.5 hydroxyalkyl, di(C.sub.1 -C.sub.5 alkyl)sulfamoyl, 6-membered heterocyclic group, phenyl, benzyl, or phenylsulfonyl each phenyl moiety of the last three members being optionally substituted by a halogen, methoxy, or methyl group; Z.sup.4 is phenyl optionally substituted by a halogen, methoxy, or methyl group or 5- or 6-membered heterocyclic group which is optionally substituted by a halogen, methoxy, or methyl group and which can be optionally condensed with a benzene ring; Z.sup.5 is thienyl or phenyl each optionally substituted by a halogen, methoxy, or methyl group; Z.sup.6 is thienyl or phenyl each optionally substituted by a halogen, methoxy, or methyl group; m is an integer from 0 to 2; n is an integer from 2 to 3) or its pharmaceutical acceptable acid addition salt being useful as a drug for senile dementia, psychotropic, or antiamnesia agent is provided through several routes.

Carbamoylpyrolidone derivatives and drugs for senile dementia

2-Substituted carbonylimidazo[4,5-c]quinolines of formula: ##STR1## having a high affinity for benzodiazepin receptor and showing an excellent psychostimulating action orally at a dose of 0.1-500 mg are provided through several routes.

2-substituted carbonylimidazo[4,5-c]quinolines

A compound of the formula: ##STR1## wherein Y is ##STR2## R is hydrogen, C.sub.1 -C.sub.5 alkyl, C.sub.1 -C.sub.5 alkanoyl, or C.sub.7 -C.sub.9 phenylalkyl, and X is hydrogen, C.sub.1 -C.sub.5 alkoxy, or halogen being useful for the treatment of senile dementia, psychoneurosis, and/or amnesia.

Pyrrolo(1,4)benzodiazepine derivatives

A compound of the formula: ##STR1## (wherein R is --SO.sub.2 R.sup.1 or --CONHR.sup.2 ; R.sup.1 is C.sub.1 -C.sub.5 alkyl, C.sub.8 -C.sub.12 phenylalkenyl, amino, dimethylamino, optionally substituted C.sub.8 -C.sub.12 aryl, or 5- or 6-membered heterocyclic group including at least one hetero atom selected from the group consisting of N, S, and O; R.sup.2 is amino, C.sub.1 -C.sub.8 alkylamino, C.sub.1 -C.sub.8 alkyl, or optionally substituted C.sub.8 -C.sub.12 aryl) or its pharmaceutically acceptable acid-addition salt, being useful as a drug for senile dementia, psychotropic, or antiamnesia agent is provided through several routes.

N-(2-oxpyrrolidin-1-yl-)acetyl)piperazine derivatives and drug for

A compound of the formula: ##STR1## (wherein R is phenyl optionally substituted by one or two members selected from the group consisting of trifluoromethyl, C.sub.1 -C.sub.5 alkyl, C.sub.1 -C.sub.5 alkoxy, C.sub.1 -C.sub.5 alkylthio, nitro, amino C.sub.1 -C.sub.5 alkanoylamino and C.sub.1 -C.sub.5 alkoxycarbonyl or 5- or 6-membered heterocyclic group optionally substituted by one or two members selected from the group consisting of halogen, C.sub.1 -C.sub.5 alkyl and C.sub.1 -C.sub.5 alkoxy,

Condensed imidazopyridine derivatives useful as psychotropic agents

Compounds of the formula (I): ##STR1## wherein R.sup.1 and R.sup.2 each is hydrogen, alkyl, alkoxycarbonyl, carboxy, halogen, nitro or trifluoromethyl, or R.sup.1 and R.sup.2 taken together may form alkylene; R.sup.3 is hydrogen, alkyl, alkanoyl or alkylsulfonyl; R.sup.4 is hydrogen, alkoxycarbonyl, carboxy or halogen; X is hydrogen, alkyl, alkoxy, halogen or hydroxy; and Y is methine or nitrogen or salts thereof are provided. The compounds (I) show potent psychotropic activity.

Pyrazolo[4,3-c]quinoline-3-one and imidazo[4,3-c]cinnolin-3-one

1,4-Benzodiazepine derivatives of the formula: ##STR1## (in which R.sup.1 is pyrrolidinyl or piperidinyl each optionally substituted by C.sub.1-3 alkyl, phenyl-C.sub.1-3 alkyl, C.sub.1-5 alkanoyl, or C.sub.2-5 alkoxycarbonyl,

Growing community of inventors

Nara, Japan

Masami Eigyo